Investor Profile: Atlas Venture — Thesis, Cheque Size & How to Apply

Founding a biotech company and wondering how to get funding from Atlas Venture? This Cambridge, Massachusetts firm is a seed-led venture creation shop that builds breakthrough biotechnology companies side-by-side with scientists and entrepreneurs. Atlas Venture funding has backed generation-defining medicines companies, and its recent raises — Fund XIV ($450M, December 2024) and Opportunity Fund III ($400M, September 2025) — keep it one of the best-capitalised early-stage biotech investors in the world. For biotech founders, Atlas is where company creation is the product.

Thesis and sweet spot

Atlas Venture was formed in 1980 in Amsterdam as a subsidiary of NMB Bank, and has been biotech-only since 2014, when its technology team spun out as Accomplice. Today it operates from a single office in Cambridge, Massachusetts, in the heart of the world's densest biotech cluster. The thesis is venture creation: rigorously selecting a focused set of investments and working alongside founders to translate high-impact science into medicines and scalable businesses.

The firm's incubator has launched 92 startups from inside Atlas itself (per its homepage) — company creation, not just company selection. The sweet spot is seed-stage biotechnology: novel science with a credible path to the clinic, where Atlas can be a founding or lead investor and stay involved through scale-up.

Cheque size and fund

Atlas does not publicly state a cheque-size range, so none is given here. Its recent fund closes are public: Fund XIV at $450M (December 2024), Opportunity Fund III at $400M (September 2025) and Opportunity Fund II at $300M (September 2021). Third-party sources report assets under management of about $2.7B, though that figure may be dated — the fund-level closes above are the firm-confirmed numbers.

Notable portfolio

The portfolio reads like a biotech hall of fame: Alnylam, Intellia Therapeutics, Kymera Therapeutics, Bicycle Therapeutics, Cogent Biosciences, Dyne Therapeutics, Disc Medicine, Korro Bio, Replimune and ArQule (all confirmed on the firm's portfolio page). These are companies built around platform science — RNA, gene editing, targeted protein degradation — exactly the high-impact bets the venture-creation model is designed for.

Partners

The investing partners in Fund XIV include Kevin Bitterman, Bruce Booth, Michael Gladstone, David Grayzel and Jason Rhodes, with Jean-François Formela also a partner. The team blends scientific and company-building backgrounds, matching the firm's scientist-founder clientele.

Programs, credits and perks

Beyond capital, Atlas runs an in-house incubator (92 startups launched), Nautilus (a leadership community for portfolio companies) and Compass (a startup playbook resource). These are portfolio-company resources rather than public accelerators, but they show how the firm systematises company building.

How to apply for funding

Atlas Venture does not publish a pitch email or application form — its listed contact ([email protected]) is for media, not pitches, and should not be used as a funding channel. Biotech founders typically reach the team through scientific-network introductions, with a pitch grounded in differentiated science and a credible development plan.